LMR Partners LLP Sells 1,634,890 Shares of GSK plc (NYSE:GSK)

LMR Partners LLP cut its stake in shares of GSK plc (NYSE:GSK - Free Report) by 81.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 384,302 shares of the pharmaceutical company's stock after selling 1,634,890 shares during the period. LMR Partners LLP's holdings in GSK were worth $12,997,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in shares of GSK by 8.6% in the 3rd quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company's stock valued at $9,052,000 after purchasing an additional 18,539 shares in the last quarter. ST Germain D J Co. Inc. grew its position in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares during the last quarter. Green Alpha Advisors LLC increased its stake in shares of GSK by 17.7% during the fourth quarter. Green Alpha Advisors LLC now owns 27,316 shares of the pharmaceutical company's stock valued at $924,000 after acquiring an additional 4,107 shares during the period. Fiduciary Alliance LLC bought a new stake in GSK during the fourth quarter worth approximately $390,000. Finally, Brookstone Capital Management boosted its holdings in GSK by 19.8% during the fourth quarter. Brookstone Capital Management now owns 31,701 shares of the pharmaceutical company's stock worth $1,072,000 after buying an additional 5,244 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GSK has been the subject of a number of recent analyst reports. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, BNP Paribas began coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $40.58.

GSK Trading Up 0.2%

NYSE:GSK traded up $0.07 during trading hours on Friday, hitting $37.64. The stock had a trading volume of 7,221,976 shares, compared to its average volume of 4,839,524. The company has a market cap of $77.65 billion, a price-to-earnings ratio of 23.67, a P/E/G ratio of 1.12 and a beta of 0.51. GSK plc has a one year low of $31.72 and a one year high of $45.80. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business's 50 day moving average is $37.39 and its 200-day moving average is $35.97.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.43 earnings per share. Sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This represents a $1.69 annualized dividend and a dividend yield of 4.48%. The ex-dividend date is Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.